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Background. Bordetella pertussis is a Gram-negative bacterium that infects the human respiratory tract and causes pertussis
or whooping cough. The disease has resurged in many countries including Finland where the whole-cell pertussis vaccine has
been used for more than 50 years. Antigenic divergence has been observed between vaccine strains and clinical isolates in
Finland. To better understand genome evolution in B. pertussis circulating in the immunized population, we developed an
oligonucleotide-based microarray for comparative genomic analysis of Finnish strains isolated during the period of 50 years.
Methodology/Principal Findings. The microarray consisted of 3,582 oligonucleotides (70-mer) and covered 94% of 3,816
ORFs of Tohama I, the strain of which the genome has been sequenced [1]. Twenty isolates from 1953 to 2004 were studied
together with two Finnish vaccine strains and two international reference strains. The isolates were selected according to their
characteristics, e.g. the year and place of isolation and pulsed-field gel electrophoresis profiles. Genomic DNA of the tested
strains, along with reference DNA of Tohama I strain, was labelled and hybridized. The absence of genes as established with
microarrays, was confirmed by PCR. Compared with the Tohama I strain, Finnish isolates lost 7 (8.6 kb) to 49 (55.3 kb) genes,
clustered in one to four distinct loci. The number of lost genes increased with time, and one third of lost genes had functions
related to inorganic ion transport and metabolism, or energy production and conversion. All four loci of lost genes were
flanked by the insertion sequence element IS481. Conclusion/Significance. Our results showed that the progressive gene
loss occurred in Finnish B. pertussis strains isolated during a period of 50 years and confirmed that B. pertussis is dynamic and
is continuously evolving, suggesting that the bacterium may use gene loss as one strategy to adapt to highly immunized
populations.
Citation: Heikkinen E, Kallonen T, Saarinen L, Sara R, King AJ, et al (2007) Comparative Genomics of Bordetella pertussis Reveals Progressive Gene Loss
in Finnish Strains. PLoS ONE 2(9): e904. doi:10.1371/journal.pone.0000904
INTRODUCTION
Bordetella pertussis is a Gram-negative bacterium that causes a highly
contagious respiratory disease, pertussis or whooping cough.
Despite extensive immunization, the disease has remained
endemic causing epidemics every 3 to 5 years. A resurgence of
pertussis has been observed in USA, Europe, Canada, Australia
and Asia [2–10]. In Finland, a whole-cell pertussis vaccine was
introduced in 1952. Although the vaccination coverage of four
doses has been high, pertussis remains endemic and the incidence
of pertussis has increased since last decade [6].
For more effective vaccination programs to prevent pertussis, it
is important to understand pathogenesis and transmission of
B. pertussis, to monitor changes in bacterial populations and to
study impact of the changes on the prevention and incidence of
disease. Different typing methods have been developed and
applied for studying molecular epidemiology of B. pertussis, such
as serotyping of fimbriae (Fim), genotyping of virulence genes,
pulsed-field gel electrophoresis (PFGE) and multi-locus variable
number of tandem repeats (MLVA) analysis [4,6,9,11–21]. These
studies revealed that the B. pertussis population is dynamic and that
antigenic divergence has occurred with respect to pertussis toxin
(Ptx), pertactin (Prn), Fim2 and Fim3 between the vaccine strains
and circulating isolates. Further, it was observed that epidemics in
many countries were associated with clonal expansion of strains.
Genome sequencing offers a global view of the genetic content
of pathogenic bacteria. Of the nine Bordetella species, annotated
genome sequences of B. pertussis, B. parapertussis, B. bronchiseptica and
B. avium have been recently published [1,22]. The sequenced B.
pertussis strain Tohama I, originally isolated in Japan in 1954, is
considered a reference strain and used for the production of
acellular pertussis vaccines. The genome of B. pertussis has 3,816
ORFs [1]. A notable feature is the high load of insertion sequence
(IS) elements and relatively high content (9.4%) of pseudogenes
[1].
Based on the available sequence, we developed an oligonucle-
otide (70-mer) microarray for comparative genomic analysis of B.
pertussis strains. Our aim was to study the evolution and molecular
epidemiology of B. pertussis strains isolated in Finland where the
whole-cell vaccine has been used for more than 50 years. Insight
into B. pertussis capacity to adapt to vaccine-induced immunity is
important for understanding the current epidemiology of pertussis
in vaccinated populations. In addition to the historical perspective,
the emphasis of strain selection was on recent isolates causing
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with those obtained by standardized typing methods.
MATERIALS AND METHODS
Bacterial strains and culture conditions
Bacterial isolates were selected from the B. pertussis strain collection
from the Pertussis Reference Laboratory of the National Public
Health Institute, Turku, Finland. The selection criteria included
the time and geographic location of isolation, and their serotypes,
genotypes and PFGE profiles [6,13,21]. A total of 20 clinical
isolates from 1953 to 2004 together with two Finnish vaccine
strains and two international reference strains, Tohama I, isolated
in Japan in 1954 and 18323, isolated in USA in 1946 were
included (Table 1). Finnish vaccine strain 18530 was obtained
from USA and has been used since 1962, and strain 1772 was
obtained from UK and was added to the vaccine in 1976. The 50-
year period was covered in a way that from 1950’s to 1980’s one to
two strains represented each decade and from 1991 onwards
strains were selected according to incidence peaks observed in the
whole country (Table 1). We have previously shown that Finnish
B. pertussis population was dynamic and has continuously evolved
[6,13,21]. Therefore, the strains selected for the present study were
representative of the most prevalent PFGE profiles from 1953 to
2004. To avoid the influence of local outbreaks, isolates from at
least two geographic locations were selected. All strains were
isolated from children younger than 12 years.
Bacteria stored in 270uC were recultured on Charcoal agar
(Oxoid Ltd, Basingstoke, England) with 10% defibrinated sheep
blood. The plates were incubated at 35–36uC for 3 days. Bacteria
were harvested and suspended in distilled water. Prior to DNA
isolation, the concentration of bacterial suspension was adjusted to
2610
9 cells/ml.
DNA isolation, digestion and hybridization
B. pertussis DNA was isolated with GenElute
TM Bacterial Genomic
DNA Kit (Sigma-Aldrich Inc., St. Louis, USA) and digested with
Sma I (10 U/mg DNA, New England Biolabs, Ipswich, USA)
according to the instructions of the labeling kit BioPrimeHArray
CGH Genomic Labeling System (Invitrogen Life Technologies,
Carlsbad, USA). The quality of digested DNA was examined by
gel electrophoresis. Digested and undigested DNA was compared
as the starting material for hybridization and no effect of the DNA
treatment on identification of absent genes was found. The
existence of restriction site (CCCGGG) of SmaI was searched into
Table 1. Characteristics of the bacterial strains and the distribution of absent genes detected by microarray.
..................................................................................................................................................
Strain Year of isolation Sero-type Pertactin allele Pertussis toxin allele PFGE-profile Locus 4 Locus 3 Locus 1 Locus 2
17.7 kb 22.7 kb 24.0 kb 8.6 kb
Tohama I 1954 Fim2 1 PtxA2 Tohama I ++++
18323
(1 1946 6 PtxA4 18323 +++
(2 +
18530
(3 Fim3 1 PtxA3 BpFINR13 ++++
1772
(4 Fim2,3 1 PtxA2 BpSR23 ++--
KKK22 1953 Fim3 1 PtxA2 BpFINR1 +++-
KKK1277 1964 Fim2,3 1 PtxA2 BpFINR1 +++-
KKK1330 1965 Fim2 1 PtxA2 BpFINR14 +++-
1977/3 1977 Fim3 1 PtxA1 BpSR23 ++--
1977/7 1977 Fim3 1. PtxA1 BpFINR9 ++--
PRCB2/H 1982 Fim2 2 PtxA1 BpSR18 ++--
PRCB20/S 1982 Fim2 2 PtxA1 BpSR46 ++--
PRCB2 1991 Fim2 2 PtxA1 BpSR1 ++--
PRCB13 1992 Fim2 2 PtxA1 BpSR1 ++--
PRCB41 1993 Fim2 2 PtxA1 BpSR1 ++--
PRCB179 1996 Fim2 2 PtxA1 BpSR147 ++--
PRCB223 1996 Fim2 2 PtxA1 BpSR147 - + --
PRCB272 1999 Fim3 2 PtxA1 BpSR11 + ---
PRCB291 1999 Fim3 2 PtxA1 BpSR5 + ---
PRCB305 1999 Fim2,3 2 PtxA1 BpSR11 + ---
PRCB374 2003 Fim3 2 PtxA1 BpSR11 + ---
PRCB382 2003 Fim3 2 PtxA1 BpSR12 + ---
PRCB406 2003 Fim3 2 PtxA1 BpSR11 + ---
PRCB461 2004 Fim3 2 PtxA1 BpSR11 + ---
PRCB474 2004 Fim3 2 PtxA1 BpSR11 + ---
Range of the lost genes in loci 1–4 is BP0910A-BP0934, BP1135-BP1141, BP1948-BP1966, and BP2088-BP2103, respectively. (+)a n d( 2) indicates presence or absence of
the locus.
1.International reference strain
2.Three genes in the locus were lost (BP0910A-BP0912).
3.Strain used for the production of whole cell vaccine in Finland since 1962 and obtained from USA.
4.Strain added to the whole cell vaccine in 1976 and obtained from UK.
doi:10.1371/journal.pone.0000904.t001
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Gene loss in B. pertussis
PLoS ONE | www.plosone.org 2 September 2007 | Issue 9 | e904DNA sequences of the 3,582 70-mer oligonucleotides used in the
microarray (see section of the oligonucleotide-based microarray).
Only 55 (1.5%) oligonucleotides were found to possess the
restriction site. Of them, 48 belonged to the genes identified as
present, five as duplicated, and two as absent, indicating that the
existence of restriction sites on oligonucleotides did not affect the
identification of absent or duplicated genes in the microarray. To
avoid the possible effect of length and conformation of long
chromosomal DNA on labelling, the digested DNA was used for
all experiments.
We next compared the amount of DNA (range: 2 to 8 mg) used
as the starting material and found no effect on identification of
absent genes. The amount of 4 mg was thus chosen for all
experiments. The 4 mg of digested DNA of the Tohama I strain
used as reference strain were labeled with Cy 3 and that of testing
strain with Cy 5 (Amersham Biosciences UK Limited, Buck-
inghamshire, England) according to the protocol of BioPrime-
HArray CGH Genomic Labeling System (Invitrogen Life Tech-
nologies, Carlsbad, USA). The labeled DNA was purified with the
purification kit of the same manufacturer and then combined. The
concentrations of Cy3 and Cy5 were measured with ND-1000
Spectrophotometer (NanoDrop Technologies, Wilmington, USA).
The volume of labeled DNA was reduced below 15.7 mli n
vacuum centrifuge, and 2.5 ml of yeast tRNA (10 mg/ml,
Invitrogen Life Technologies, Carlsbad, USA), 4.3 mlo f
206SSC (16SSC was 8.8 g/l NaCl and 4.4 g/l trisodiumcitrate)
and 0.8 ml of 10% SDS were added. After denaturation at 100uC
for 3 min, 1.7 mlo f1 0 6Blocking Solution from DIG-Wash and
Block Buffer set–kit (Roche, Mannheim, Germany) was added.
The final volume for hybridization was adjusted with water to
25 ml. Before hybridization, slides were fixed by UV-cross linking
with 90 mJ cm
22, washed for 1 min in 0.1% of SDS and 2 min in
water to remove residual salt, and incubated at 50uC for 30 min in
BSA solution containing 1% of BSA fraction V, 26SSC and 0.1%
of SDS to block nonspecific binding. The slides were further
washed in 26SSC for 3 min and then in 0.26SSC for 3 min.
Hybridization was conducted under 22625 mm LifterSlip
TM
coverslip (Erie Scientific Company, Portsmouth, USA) in hybrid-
ization chamber at 65uC for 16 h. To control humidity inside the
hybridization chamber, a strip of thin paper, humidified with
approximately 100 ml of 3.46SSC, was placed under the slide.
After hybridization slides were washed at 65uC for 10 min with
16SSC and 0.1% of SDS. The following washes were conducted
at room temperature for 10 min with 0.56SSC and 0.01% SDS,
and for 3 min and 1 min with 0.16SSC. Slides were dried in slide
centrifuge and scanned with ScanArray H5000 (PerkinElmer,
Waltham, USA).
Oligonucleotide-based microarray
The oligonucleotides used in the microarray were designed in
collaboration with Operon Biotechnologies GmbH (Cologne,
Germany), and an Array-Ready Oligo Set
TM was purchased from
the Operon. The set of 3,582 70-mer oligonucleotides, where one
oligonucleotide corresponded to one gene, covered 94% of 3,816
ORFs of B. pertussis Tohama I [1]. Lyophilized oligonucleotides
were dissolved in 50% of DMSO and 26SSC to the concentration
of 20mM. The oligonucleotides were spotted on UltraGaps
TM
coated slides (Corning Life Sciences, Acton, USA) with ‘‘R-ray’’,
an in-house spotter in the Finnish DNA Microarray Centre, the
Centre for Biotechnology, Turku, Finland. Each oligonucleotide
was spotted twice. A total of 20 randomized negative controls with
no match to DNA of B. pertussis Tohama I were spotted in 8
separate spots to control non-specific binding. Contamination of
printing tips and non-specific binding of DNA to slide surface was
controlled by spotting water and buffer in 244 spots. Oligonucleo-
tides representing 12 house-keeping genes of B. pertussis were
spotted 10 times and used as positive controls to monitor the intra-
array variation of the hybridization.
Image processing, data analysis and statistical
testing
Image processing was made using ScanAlyze program from
Michael B. Eisen, (Univerity of California at Berkeley). MA-plot,
where mean of intensity (A) is plotted against log-transformed
intensity ratio (M) of each spot, was created for classifying the
genes present or absent in the testing strain. In the MA-plot,
majority of the M-values was centered to zero, and a clearly
separated group of genes was formed with low M-values (Figure 1).
As the group was completely separated from the majority,
genes included in the group were considered as absent and filtered
from the raw data by defining M-value,22. Student’s t-test was
used to determine the difference in log-ratios between present
and absent genes and p-value,0.05 considered the statistically
significant.
Confirmation of microarray results with PCR
PCR was used to confirm absent genes of the testing strains
identified by microarray. The primers were designed with Primer3
program (Steve Rozen&Helen J. Skaletsky, 2000) on the basis of
the two genes which flanked the lost locus or of the two genes
located at each end of the lost locus. The sequences of the primers
and their target genes were shown in Table S1.
PCR reaction contained 5–50 ng of purified DNA, 200 mMo f
each dNTP (Promega, Madison, WI, USA), 20 pmol of primers
(Sigma Aldrich, Haverhill, UK), 5% DMSO (Merck, Darmstadt,
Germany), 16Buffer II, 1.5–3 mM of MgCl2, 0.625–2.5 U of
AmpliTaq GoldH DNA polymerase (Applied Biosystems, Foster
City, USA). The reaction volume was adjusted to 50 ml with
Molecular Biology grade water (Eppendorf, Hamburg, Germany).
PCR was run in MJ Research PTC 200 Thermal Cycler
(Global Medical Instrumentation, Ramsey, USA) with the
following protocol: initial denaturation at 95uC for 8 min followed
by 30–38 cycles of 30 sec at 94uC, 30 sec to 1 min at 60–62uC and
1 to 3 min at 72uC, and with a final elongation of 5 min at 72uC.
The expected size of PCR products was confirmed by gel
electrophoresis.
RESULTS
Population of B. pertussis in Finland
More than 400 clinical isolates collected since 1953 have been
analyzed by serotyping of Fim, genotyping of pertussis toxin S1
subunit (ptxA) and pertactin (prn), and PFGE [6,13,21]. The strains
isolated in 1953–1965 had the same ptxA as the vaccine strains
(ptxA2), but a change to ptxA1 occurred in the 1970’s (Table 1).
During the 1980’s, a change from prn1 (the vaccine type) to prn2
(non-vaccine type) was observed. We have previously shown that
Finnish B. pertussis population was dynamic and has continuously
evolved [6,21]. The most prevalent PFGE profiles found during
the period of 50 years were BpFinR1 in 1953–1965, BpSR23 in
1970s and BpSR18 in 1980’s (Figure 2). From 1991 to 2004 the
predominant profiles were BpSR1, BpSR147 and BpSR11
(Figure 2, Table 1). BpSR11 strains started to emerge in 1999,
and its frequency reached 55% in 2003 and 42% in 2004, when
the nationwide epidemic of pertussis occurred (unpublished data).
Along with BpSR11, BpSR12 emerged in 2000, and the highest
frequency (16%) for the profile was detected in 2003. Another
Gene loss in B. pertussis
PLoS ONE | www.plosone.org 3 September 2007 | Issue 9 | e904profile that co-emerged with BpSR11 was BpSR5, for which the
frequency in 1999 was 7%. PFGE profiles of all clinical isolates
analyzed were clearly different from that of Tohama I strain, strain
18323 and the Finnish vaccine strain 18530 (Figure 2) [6,21]. The
other Finnish vaccine strain 1772 represented BpSR23, the
predominant PFGE profile in 1970s. The relatedness between
Tohama I and strain 18323 was less than 50% (Figure 2).
Performance of the microarray
The oligonucleotide-based microarray was proved to be specific
for B. pertussis because no hybridization was observed to
randomized negative control spots or water spots. Only marginal
variation in the log-ratios was observed when self to self
hybridization of DNA of the reference strain and dye swap of
DNA of the testing strain were tested.
Figure 2. Dendrogram analysis of PFGE profiles of B. pertussis clinical and reference strains. The DNA profiles obtained after restriction with XbaI
are shown, and only different PFGE profiles identified among the strains tested by microarray were included. The unweighted pair group method
using arithmetic averages (UPGMA) with 1% band tolerance and 1% optimization settings was used as the clustering method.
doi:10.1371/journal.pone.0000904.g002
Figure 1. MA-plot analysis of microarray results of a B. pertussis clinical strain (PRCB179). The mean of intensity (A) is plotted against log-
transformed intensity ratio (M) of individual spots. Two distinct clusters of the genes are shown. The genes present in both reference and testing
strains were centered on zero, and the genes lost in the testing strain formed a separate cluster defined by M-value,22.
doi:10.1371/journal.pone.0000904.g001
Gene loss in B. pertussis
PLoS ONE | www.plosone.org 4 September 2007 | Issue 9 | e904The 12 housekeeping genes with multiple spots (ten per array)
were used for the determination of intra-array variation. The
mean of signal intensity ratio (reference strain vs testing strain)
ranged from 1.03 to 1.29 and SD from 0.04 to 0.08. The
coefficient of variation (CV) was thus 3.37 to 6.76%. Number of
absent genes detected was proved to be constant among all the
replicate spots. For the determination of inter-array variation, 12
virulence genes present in the testing strain were chosen. Six
individual results from three separate arrays were calculated. The
mean of signal intensity ratio (reference strain vs testing strain)
ranged from 0.99 to 1.40 and SD from 0.04 to 0.09. The CV was
thus 3.52 to 8.38%.
Gene loss in B. pertussis strains
Compared with the strain Tohama I, four distinct loci were
identified to be absent among the Finnish clinical isolates (Table 1).
Relative to the Tohama I chromosome, the number of genes
absent was 24 (size: 24 kb) for locus 1 (range: BP0910A-BP0934),
seven (8.6 kb) for locus 2 (BP1135-BP1141), 18 (22.7 kb) for locus
3 (BP1948-BP1966), and 16 (17.7 kb) for locus 4 (BP2088-
BP2103). However, the four loci were present in the international
reference strain 18323 and in the Finnish strain 18530 that has
been used for vaccine production since 1962. The other strain,
1772 that was added to the vaccine in 1976, missed the loci 1 and
2. Microarray data has been deposited in Gene Expression
Omnibus database (http://www.ncbi.nlm.nih.gov/projects/geo/)
and is accessible through accession number GSE8092.
Twenty clinical isolates from the period 1953 to 2004 were
analyzed with the microarrays. All three strains analyzed from
1953–1965 missed only one locus (Locus 2). All nine strains
analyzed from 1977 to 1996 missed two loci (Loci 1 and 2). Finally,
all eight strains analyzed from 1999 to 2004 missed the Loci 1 and
2 in addition to Locus 3. Altogether, the eight strains had 44
absent genes (55.3 kb) in the three different loci. Only the strain
PRCB223 which was isolated in 1996 was found to miss Locus 4
(Table 1). The absence of the four lost loci was confirmed by PCR
(Table S2).
Based on genome sequence of the strain Tohama I, all the four
absent loci were flanked by IS481.
Although the four absent loci identified among the 20 clinical
isolates were present in the reference strain 18323 and the Finnish
vaccine strain 18530, additional absent loci were found in the two
strains (Dataset S1). Strain 18323 had 196 absent genes identified
in 23 loci and the number of genes in each locus ranged from 1 to
33. Of the 23 absent loci, nine were bordered by IS481 and 14 had
IS481 adjacent to one side. The Finnish vaccine strain 18530 had
22 absent genes in five different loci and the number of genes in
each locus ranged from 1 to 9 (Dataset S1). Of the five loci, four
were bordered by IS481 and one had IS481 adjacent to one side.
Two loci (BP2627-BP2629 and BP3104-BP3110) were absent in
both strains 18323 and 18530. A single gene (BP1225), flanked on
one side by IS481, was absent in two clinical strains KKK1277
and 1330, isolated in 1964 and 1965, respectively.
Gene duplication in B. pertussis strain
Of the 20 clinical isolates, one strain KKK1330 was found to have
both gene loss and duplication. This strain was isolated in 1965
and had a PFGE profile BpFINR14 distinct from the prevalent
profile BpFinR1 found in 1950s and 1960s (Figure 2, Table 1).
The strain missed locus 2 (BP1135-BP1141), whereas two loci were
duplicated (i.e. BP1288-BP1442 and BP1481-BP1487). The mean
of log-transformed intensity (mean6SD: 0.4860.22) of all the
duplicated genes was significantly higher than that of all other
present genes (20.3660.26, p,0.001). When the mean of log-
transformed intensity was compared between the duplicated genes
and all other present genes of the strain KKK1277 isolated in
1964, no significant difference was observed (p=0.181). IS481 was
found adjacent to one side of the locus BP1288-BP1442.
Characteristics of the absent and duplicated genes
In the genome of the strain Tohama I, the percentage of the
pseudogenes was 9.4% and average of the GC contents was 67.6%
[1]. Of the 65 lost genes identified in 4 different loci, 11 (16.9%)
were pseudogenes. The average percentage of pseudogenes is
significantly higher than that in the genome of Tohama I strain
(chi-squared test, p=0.047). The corresponding percentages in the
loci were 28.6%, 16.7%, 30.8% and 12.5%, respectively. The GC
content of the lost genes in each locus was 69.6%, 66.0%, 70.4%
and 68.9%, respectively.
A total of 23 functional categories of genes were defined in the
Tohama I strain according to the Clusters of Orthologous Groups
(COG) [1]. On the basis of the COG, functions of the absent and
duplicated genes were compared with that of the strain Tohama I.
The number of genes which could be classified into the COG
categories are shown in Table 2 and included in the comparison
(Figure 3). Of the 23 functional categories of genes, 20 were
included in the comparison (Figure 3), because none of the absent
or duplicated genes belonged to the categories of RNA processing
and modification, cell cycle control and chromatin structure and
dynamics.
For the clinical isolates, most notable were high frequencies of
absent genes identified in the two functions: inorganic ion transport
and metabolism (N=8) and energy production and conversion
(N=7), representing one third (15/44) of total number of absent
genesclassifiedintheCOG(Figure3).Theeightgenesdefinedinthe
function of inorganic ion transport and metabolism included two
coding for putative ferric siderophore receptors (BP1138 and
BP1962), two for probable inner membrane components of
binding-protein-dependent transport system (BP0914 and
BP0915), putative exported protein (BP0913), putative signal
Table 2. Number of absent and duplicated genes detected in Finnish clinical strains and vaccine strain and the reference strain
relative to the genome of B. pertussis Tohama I.
..................................................................................................................................................
Strain (s) No of absent genes No of duplicated genes No of genes defined in COG (%) No of Pseudogenes (%)
All clinical strains 65 0 44 (67,7) 11 (16,9)
Vaccine strain 18530 22 0 12 (54,5) 5 (22,7)
Reference strain 18323 196 0 118 (60,2) 19 (9,7)
KKK 1330 7 129 92 (71,3)
(1 16 (12,4)
1.No of duplicated genes defined in COG
doi:10.1371/journal.pone.0000904.t002
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PLoS ONE | www.plosone.org 5 September 2007 | Issue 9 | e904transduction protein (BP1137), putative flavocytochrome (BP1961),
and putative dioxygenase hydroxylase component (BP2091). The
seven genes defined in the function of energy production and
conversion were putative succinate-semialdehyde dehydrogenase
[NADP+] (BP0919), putative exported protein (BP0920), citrate
utilization protein B (BP0921), probable oxidoreductase (BP1953),
putative monooxygenase (BP1954), putative ferredoxin (BP2095)
and putative fatty-acyl-CoA racemase (BP2096).
There were seven absent genes identified in the function of
amino acid transport and metabolism. Of the seven genes, five
(BP1948-BP1951 and BP1957) were in locus 3 and two (BP2089
and BP2090) in locus 4. Four genes (BP1950, BP1951, BP2089
and BP2090) were associated with ATP binding cassette (ABC)
systems which are responsible for the import and export of a wide
variety of molecules across cell membranes of bacteria [23].
Of the five absent genes defined as function unknown, three
(BP0923, BP0927 and BP0931) were in locus 1, one (BP1965) in
locus 3 and one (BP2103) in locus 4. Four genes coded for putative
exported proteins.
We have not observed any absent or duplicated genes that
encoded known virulence factors of B. pertussis.
For the vaccine strain 18530, 12 of 22 absent genes were
classified in the COG. Of the 12 genes, three belonged to the
function for inorganic ion transport and metabolism (Figure 3).
For the reference strain 18323, the missing genes were found in
17 of 20 functional categories. The three categories without
missing genes were replication, recombination and repair, cell
cycle control, mitosis and meiosis, and nucleotide transport and
metabolism (Figure 3).
For the strain KKK1330, the duplicated genes were found in
the following functional categories: cell motility, intracellular
trafficking and secretion, cell wall/membrane biogenesis, and
posttranslational modification, protein turnover, chaperones
(Figure 3). A number of duplicated genes were related to flagella.
DISCUSSION
A resurgence of pertussis has been observed in many countries,
despite high vaccine coverage [2–10]. The causes for the
resurgence are multiple, such as increased awareness of the
disease, use of better microbiological diagnosis and different
effectiveness of the vaccines used, waning vaccine-induced
immunity and pathogen adaptation. Indeed, antigenic divergence
has been found between B. pertussis vaccine strains and circulating
isolates in the countries with the re-emergence of the disease [4–
6,8,9,12–16]. Analyses of B. pertussis clinical isolates using PFGE or
MLVA further revealed the clonal expansion of certain strains
which caused recent epidemics in the countries [6,16–21].
Vaccination against pertussis has been introduced in Finland
since 1952. The vaccine is produced at the National Public Health
Institute, Helsinki, Finland. Strain 18530 has been used since
1962, and strain 1772 was added to the vaccine in 1976. The
vaccine has not changed since then, and the vaccination coverage
for four doses has been 95%. To better understand the evolution
of B. pertussis in immunized populations, an oligonucleotide-based
microarray was developed and used for comparative genomic
analysis of Finnish strains isolated during a period of 50 years.
Compared with the genome of strain Tohama I, a progressive
gene loss was observed among the Finnish clinical strains. Strains
Figure 3. Distributions of lost and duplicated genes defined in the 20 functions based on the Clusters of Orthologous Groups. Number of the
genes is shown in Table 2.
doi:10.1371/journal.pone.0000904.g003
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Tohama I, with only seven genes absent. A marked change with
the deletion of 24 genes occurred in strains isolated in 1970’s,
more than 20 years after the vaccination was introduced. The
gene content of the strains isolated from the following 20 years
remained basically the same. The next major deletion of 18 genes
was first detected in strains isolated in 1999, and the gene content
of strains isolated throughout the following period remained
unchanged. Our data confirmed that B. pertussis population is
dynamic and is continuously evolving [6,13,21], suggesting that
the bacterium uses gene loss as one strategy for its better
adaptation to the highly vaccinated populations. For the future,
it is of particular interest to compare our results with those
obtained from strains isolated from the same period and from
a non-vaccinated population.
Our results obtained from the oligonucleotide-based microarray
are consistent with two recent studies of B. pertussis strains using
cDNA microarray [24,25]. In addition, we detected a new lost
locus that contained 16 genes. However, the lost locus was only
found in one among the 20 clinical strains studied.
In agreement with two recent studies, none of genes coding for
known virulence factors were found to be lost in the Finnish strains
[24,25] , suggesting that virulence factors are critical for B. pertussis to
maintain its capability in the transmission and pathogenesis among
the human populations. However, changes in known virulence
factors pertussis toxin, pertactin and fimbriae coincided with the loss
of loci 1 and 3. Since 1977, when the locus 1 was lost, the
predominant allele for the gene encoding subunit 1 of pertussis toxin
had changed from ptxA2 to ptxA1. Five years after the change in ptxA,
pertactin allele shifted from prn1 to prn2. Both alleles are different
fromthe onesinthestrainsusedforFinnishwholecellvaccine.From
1976 to 1998, about 90% of the Finnish isolates expressed Fim2.
Since 1999, two nationwide epidemics occurred. In addition to the
gene loss of locus 3, the common feature between the strains mainly
responsible for the epidemics is the expression of Fim3.
Pseudogenes are usually formed due to frameshift mutation,
mutations leading to the insertion of a stop codon or insertion of IS
elements [26]. The percentage of the pseudogenes identified among
the four lost loci was significantly higher than that in the whole
genome, suggesting that the pseudogenes are prone to deletion
during theevolutionofB.pertussis.Inaddition,we haveobservedthat
the deleted regions havea slightly higher GC content compared with
the whole genome (respectively, 68.7% and 67.6%).
Gene loss or genome reduction has been observed in several
mammalian pathogens, and IS elements are found to play an
important role in this process, in addition to causing chromosomal
rearrangements and insertion mutations [27–30]. A recent study
has shown that IS-mediated diversification in Enterococcus faecium
strongly contributed to its adaptation to hospital environment
[30].During its evolution from B. bronchiseptica like ancestor, B.
pertussis has undergone significant gene loss, most likely due to IS
elements [1,31]. Three distinct IS elements were found in the
genome of B. pertussis Tohama I strain, with the copy number of
238 for IS481, 6 for IS1002 and 17 for IS1663 [1]. Interestingly,
all the four loci of lost genes identified among Finnish isolates were
flanked by IS481. Furthermore, IS481 was located at least on one
side of all loci of lost or duplicated genes detected in this study.
Taken together, the results clearly showed that IS481 plays
a critical role in the B. pertussis evolution.
It is of particular interest that one third of the lost genes had
functions related to inorganic ion transport and metabolism and
energy production and conversion. The acquisition of iron, which
is an inorganic ion, is critical for pathogenic micro-organisms,
because concentration of free iron is limited in the human host
[32]. In order to acquire iron, bacterial pathogens produce iron-
chelating compounds (siderophores). Like B. bronchiseptica, B.
pertussis contains an operon encoding the production, export and
uptake of the siderophore alcaligin [33,34]. Iron obtained from
siderophores is internalized through TonB-dependent outer-
membrane ferric complex receptors. B. bronchiseptica has 16 genes
coding for these receptors, whereas B. pertussis has lost 3 of the
genes during its evolution from B. bronchiseptica like ancestor, while
one of the remaining was pseudogene [1]. Two of the 12
functional genes coding for the receptors were deleted among the
Finnish strains isolated from 1999. These strains were responsible
for the nationwide epidemics observed in the country [6,21]. It
remains to be shown if these deletions confer a selective advantage
of the epidemic-causing strains.
In this study, seven lost genes had functions in amino acid
transport and metabolism, four of which encoded ATP binding
cassette (ABC) transporter components and were located in two
distinct loci. ABC transporters are a large group of proteins which
have roles in important cellular functions such as import and
export of various substances including iron chelators (siderophores)
[23]. According to the Tohama I chromosome, 80 ABC transporter
components have been identified [1]. Many ABC transporter
components are surface associated and are involved in virulence of
pathogenic bacteria [23]. It is known that the surface associated and
secreted proteins usually interact with host cells, and therefore are
potential immune targets. Deletion of such genes might confer
a selective advantage during infection or transmission in vaccinated
population. In line with this observation, we also found several lost
genes which coded for putative exported proteins.
PFGE has been shown to have best discriminatory power for the
study of the epidemiology of B. pertussis. More than 400 Finnish
clinical isolates collected from 1953 have been analyzed by PFGE,
and altogether about 60 PFGE profiles have been identified [6,21].
One PFGE profile BpSR11 has emerged since 1999 and become
predominant. The strains with BpSR11 were associated with the
recent nationwide epidemic in the country. Interestingly, all the
strains with BpSR11 analyzed in the present study had a lost locus
(Locus 3) of 18 genes with the length of 22,700 base pairs.
Among the 20 clinical strains studied, only one was found to
have both gene loss and duplication. The duplicated genes were
associated with the functions of cell motility, intracellular
trafficking and secretion, cell wall/membrane biogenesis, and
posttranslational modification, protein turnoverand chaperones.
Most interesting was that a number of duplicated genes were
related to flagella. Flagella are usually expressed in the Bvg
2-phase
and involved in the survival of the bacteria in the environment. In
B. pertussis, the flagellar operon was considered to be inactivated
due to multiple pseudogenes and IS insertions [1]. It is of interest
to study if the B. pertussis strain in which flagellar genes were
duplicated can express the flagella and is motile.
In this study, the oligonucleotides used for microarray were
designed from the genome of the Tohama I strain [1]. We were
able to clearly distinguish between the presence, absence or
duplication of genes among the clinical strains studied. A
drawback of microarray-based comparative genomic analysis is
that it cannot detect genes that are not present in the Tohama I
strain. Although the acquisition of ‘‘new’’ genetic material does not
seem to be a significant source of genetic variation in B. pertussis
[1,31], it is worthwhile to sequence the genome of recent B.
pertussis isolate(s) and to show how representative the strain
Tohama I, which is used for the production of a number of
pertussis vaccines, is. Furthermore, sequencing of recent isolate(s)
may identify genes acquired by B. pertussis which play a role in the
persistence and resurgence of pertussis despite vaccination.
Gene loss in B. pertussis
PLoS ONE | www.plosone.org 7 September 2007 | Issue 9 | e904In conclusion, this microarray based on 70-mer oligonucleotides
proves to be a powerful tool for comparative genomic analysis of
B. pertussis strains. Our results showed that the progressive gene loss
mediated by the homologous recombination between IS elements
occurred in B. pertussis strains in Finland, where the vaccination
against pertussis has been used for more than 50 years. The recent
epidemic-causing strains showed the largest degree of gene loss
compared with the vaccine strains. The high consistency in gene
loss could imply the presence of antigenic determinants among lost
genes and gene loss may be one strategy for B. pertussis to adapt to
highly vaccinated populations.
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